155 related articles for article (PubMed ID: 25953977)
1. VWF propeptide in defining VWD subtypes.
Haberichter SL
Blood; 2015 May; 125(19):2882-3. PubMed ID: 25953977
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.
Sanders YV; Groeneveld D; Meijer K; Fijnvandraat K; Cnossen MH; van der Bom JG; Coppens M; de Meris J; Laros-van Gorkom BA; Mauser-Bunschoten EP; Leebeek FW; Eikenboom J;
Blood; 2015 May; 125(19):3006-13. PubMed ID: 25673639
[TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
4. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
Sztukowska M; Gallinaro L; Cattini MG; Pontara E; Sartorello F; Daidone V; Padrini R; Pagnan A; Casonato A
Br J Haematol; 2008 Oct; 143(1):107-14. PubMed ID: 18691167
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor propeptide: biology and clinical utility.
Haberichter SL
Blood; 2015 Oct; 126(15):1753-61. PubMed ID: 26215113
[TBL] [Abstract][Full Text] [Related]
6. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant.
Casonato A; Sartorello F; Cattini MG; Pontara E; Soldera C; Bertomoro A; Girolami A
Blood; 2003 Jan; 101(1):151-6. PubMed ID: 12393698
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of von Willebrand disease.
Mazurier C; Ribba AS; Gaucher C; Meyer D
Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics of type 2 von Willebrand disease.
Fressinaud E; Mazurier C; Meyer D
Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
[TBL] [Abstract][Full Text] [Related]
10. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease.
Casonato A; Daidone V; Padrini R
Semin Thromb Hemost; 2011 Jul; 37(5):456-63. PubMed ID: 22102187
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice.
Jacobi PM; Kanaji S; Jakab D; Gehrand AL; Johnsen JM; Haberichter SL
J Thromb Haemost; 2018 Mar; 16(3):546-554. PubMed ID: 29285851
[TBL] [Abstract][Full Text] [Related]
12. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
13. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
Eikenboom J; Federici AB; Dirven RJ; Castaman G; Rodeghiero F; Budde U; Schneppenheim R; Batlle J; Canciani MT; Goudemand J; Peake I; Goodeve A;
Blood; 2013 Mar; 121(12):2336-9. PubMed ID: 23349392
[TBL] [Abstract][Full Text] [Related]
14. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
15. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.
Ozel AB; McGee B; Siemieniak D; Jacobi PM; Haberichter SL; Brody LC; Mills JL; Molloy AM; Ginsburg D; Li JZ; Desch KC
J Thromb Haemost; 2016 Sep; 14(9):1888-98. PubMed ID: 27359253
[TBL] [Abstract][Full Text] [Related]
17. A new candidate mutation (N528S) within the von Willebrand factor propeptide identified in a Japanese patient with phenotype IIC of von Willebrand disease.
Gaucher C; Uno H; Yamazaki T; Mashiba H; Mazurier C
Eur J Haematol; 1998 Aug; 61(2):145-8. PubMed ID: 9714529
[TBL] [Abstract][Full Text] [Related]
18. Genetic determinants of enhanced von Willebrand factor clearance from plasma.
Seidizadeh O; Baronciani L; Pagliari MT; Cozzi G; Colpani P; Cairo A; Siboni SM; Biguzzi E; Peyvandi F
J Thromb Haemost; 2023 May; 21(5):1112-1122. PubMed ID: 36754679
[TBL] [Abstract][Full Text] [Related]
19. von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention.
Yadegari H; Biswas A; Ahmed S; Naz A; Oldenburg J
Hum Mutat; 2021 Jun; 42(6):731-744. PubMed ID: 33942438
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease.
Lanke E; Kristoffersson AC; Philips M; Holmberg L; Lethagen S
Thromb Haemost; 2008 Aug; 100(2):211-6. PubMed ID: 18690339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
